Table 4.
Outcomes of SGLT2-I users versus non-SGLT2-users.
| Total (N = 646) |
SGLT2-I users (N = 111) |
Non-SGLT2-I users (N = 535) |
P-value | |
|---|---|---|---|---|
| In-hospital outcomes | ||||
| Cardiovascular-death, n (%) | 19 (2.9) | 0 (0) | 19 (3.6) | 0.041 |
| Arrhythmia, n (%) | 91 (14.1) | 7 (6.3) | 84 (15.7) | 0.010 |
| New-onset AF, n (%) | 56 (8.7) | 5 (4.5) | 51 (9.5) | |
| VT/VF, n (%) | 35 (5.4) | 2 (1.8) | 33 (6.2) | |
| Re-AMI, n (%) | 7 (1.1) | 1 (0.9) | 6 (1.1) | 0.838 |
| Re-PCI, n (%) | 13 (2.0) | 4 (3.6) | 9 (1.7) | 0.190 |
| LABP, n (%) | 23 (3.6) | 4 (3.6) | 19 (3.6) | 0.978 |
| CI-AKI, n (%) | 68 (10.5) | 6 (5.4) | 70 (13.1) | 0.022 |
| Hospital stay, days | 5 [4–8] | 5 [4–8] | 5 [4–8] | 0.526 |
| Long-term outcomes (*) | ||||
| All-cause deaths, n (%) | 76 (12.2) | 7 (6.3) | 69 (13.4) | 0.037 |
| Cardiovascular-death, n (%) | 54 (8.6) | 4 (3.6) | 50 (9.7) | 0.036 |
| Re-AMI, n (%) | 39 (6.2) | 6 (5.4) | 33 (6.4) | 0.759 |
| Re-PCI, n (%) | 53 (8.5) | 11 (9.9) | 42 (8.2) | 0.551 |
| HF Hospitalization, n (%) | 104 (16.6) | 7 (6.3) | 97 (18.9) | 0.001 |
| MACE, n (%) | 160 (25.6) | 14 (12.6) | 146 (28.4) | <0.001 |
| ICD, n (%) | 44 (6.8) | 7 (1.1) | 37 (5.7) | 0.817 |
Long term outcomes (*): total numbers of patients discharge alive (N = 625): SGLT2-I users (N = 111) and non-SGLT2-I users (N = 514).
Abbreviations: AF=Atrial Fibrillation; VT=Ventricular Tachycardia; VF=Ventricular Fibrillation; AMI=Acute Myocardial Infarction, PCI=Primaiy Percutaneous Coronary Intervention; IABP=Intra-Aortic Balloon Pump; CI-AKI=Contrast-Induced Acute Kidney Injury; HF=Heart Failure; MACE=major adverse cardiovascular events; ICD=Implantable-Cardioverter-Defibrillator.